AngioDynamics Extends Licensing Agreement With Interface Biologics to Include Central Venous Catheters (CVCs)

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALBANY, N.Y., Sept. 23, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, and Interface Biologics Inc. (IBI), a privately-held commercial stage developer of transformative biomedical-polymer products, announced AngioDynamics' exclusive Endexo technology licensing agreement for peripherally inserted catheters (PICCs), ports and dialysis catheters, now includes Central Venous Catheters (CVCs).

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC